Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Nicotinamide in Discoid Lupus Erythematosus
NCT05362188Phase 1Completed
- Sponsor
- Al-Azhar University
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nicotinamide in discoid lupus erythematosus (DLE) (3 arms), sponsored by Al-Azhar University. Primary endpoints: Severity index at 2 months and Activity score at 2 months. Started Mar 2022; status: completed.
02
Drugs
nicotinamide
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on NCT05362188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362188.